Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have been assigned an average recommendation of “Buy” from the eight research firms that are presently covering the company, MarketBeat reports. Eight investment analysts have rated the stock with a buy rating. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $6.63.

Several research analysts have commented on the company. Chardan Capital reaffirmed a “buy” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research report on Wednesday, February 26th. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, February 27th.

Taysha Gene Therapies Stock Performance

TSHA opened at $1.72 on Tuesday. The firm has a market cap of $352.60 million, a price-to-earnings ratio of 2.73 and a beta of 0.91. Taysha Gene Therapies has a 52 week low of $1.19 and a 52 week high of $4.32. The business’s 50 day moving average is $1.65 and its two-hundred day moving average is $1.94. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01. The company had revenue of $2.02 million for the quarter, compared to analyst estimates of $2.05 million. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. On average, research analysts predict that Taysha Gene Therapies will post -0.35 EPS for the current year.

Institutional Trading of Taysha Gene Therapies

A number of institutional investors have recently modified their holdings of the business. Hsbc Holdings PLC boosted its stake in shares of Taysha Gene Therapies by 65.6% in the fourth quarter. Hsbc Holdings PLC now owns 20,391 shares of the company’s stock valued at $36,000 after buying an additional 8,076 shares in the last quarter. Virtus ETF Advisers LLC boosted its position in Taysha Gene Therapies by 43.0% during the fourth quarter. Virtus ETF Advisers LLC now owns 31,597 shares of the company’s stock worth $55,000 after purchasing an additional 9,494 shares in the last quarter. Geode Capital Management LLC boosted its position in Taysha Gene Therapies by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 3,572,349 shares of the company’s stock worth $6,182,000 after purchasing an additional 9,591 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Taysha Gene Therapies by 2.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company’s stock worth $820,000 after purchasing an additional 11,390 shares in the last quarter. Finally, Creative Planning purchased a new stake in Taysha Gene Therapies during the third quarter worth $28,000. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.